Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
|Videos|March 21, 2018
Hemorrhage Risk and Anticoagulation: Implications of Brain Microbleeds
Author(s)Andrew N. Wilner, MD
5 key facts about the association between cerebral microbleeds and risk of future intracerebral hemorrhage in patients with afib who take oral anticoagulants after ischemic stroke.
Advertisement
Dr. Wilner discusses 5 key facts about the association between cerebral microbleeds and risk of future intracerebral hemorrhage in patients with afib who take oral anticoagulants after ischemic stroke.
Dr Wilner is Associate Professor of Neurology at the University of Tennessee Health Science Center and a staff physician at Regional One Health in Memphis, TN. Dr. Wilner's latest book,
Further reading:
Charidimou A, Karayiannis C, Song TJ, et al.
Advertisement
Related to this article
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]
All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
2
MDS Congress 2026: Late-Breaking Data Snapshot
3
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4
The Road Ahead for Precision Medicine in Multiple Sclerosis
5